Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative neoplasm/myelodysplastic syndrome (MPN/MDS) overlap or high risk chronic myelomonocytic leukemia (CMML). Axatilimab is an antibody that is cloned from a single white blood cell that is known to be able to recognize cancer cells and block a protein on the surface of the white blood cells that may be involved in cancer cell growth. By blocking the proteins, this may slow or halt the growth of the cancer. Azacitidine is in a class of medications called antimetabolites. It works by stopping or slowing the growth of cancer cells. Giving axatilimab with or without azacitidine may be safe and effective in treating patients with advanced phase MPN, MPN/MDS overlap or high risk CMML.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzona diagnoza zespołu mielodysplastycznego lub mieloproliferacyjnego (wg klasyfikacji WHO 2016)
- •Pacjenci, którzy nie są kandydatami do intensywnej chemioterapii ze względu na wiek lub ogólny stan zdrowia
- •Faza Ib: pacjenci po wznowie lub oporni na leczenie, którzy otrzymali co najmniej 2 cykle terapii
- •Faza II: pacjenci bez wcześniejszego leczenia (z wyjątkiem hydroksyureum, ruksolitinibu lub maksymalnie 2 cykli specjalnych leków)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 27, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Ohio State University Comprehensive Cancer Center
Columbus, United States
Trial contact
The Ohio State University Comprehensive Cancer Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.